Voluntary announcement results from multiple studies of innovative drugs at 2026 esmo congress
Filed with HKEX · Stock code 6990 ·
6ix is reading this filing.
View original source (HKEXnews)Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. on 6ix
Earlier from Sichuan Kelun-Biotech Biopharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
- 2026 Interim report
- Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
- Kelun-Biotech Announces 2026 Interim Results
Follow Sichuan Kelun-Biotech Biopharmaceutical into a list and get an email when it puts out news.
Follow Sichuan Kelun-Biotech Biopharmaceutical